Oncternal Therapeutics (ONCT) Competitor Comparison
We are evaluating the key criteria listed to compare Oncternal Therapeutics (ONCT) against its competitors in the Biotechnology industry.
Market Capitalization
315 / 368Gross Profits
180 / 278Total Revenue
247 / 300EBITDA
0 / 337Free Cashflow
139 / 352Quick Ratio
117 / 357Earnings per Share
338 / 359Dividend yield
0 / 6Total Cash
274 / 358Performance 3 years
359 / 368Performance 5 years
354 / 368Performance 10 years
350 / 368Linearity 3 years
302 / 368Linearity 5 years
258 / 368Linearity 10 years
149 / 368Total Rank
342 / 368Dividend Rank
228 / 368Valuation Rank
224 / 368Piotroski Rank
332 / 368Muliplier Rank
171 / 368Linearity 3 years - ONCT ranking 302 / 368
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.